Abstract:Background: Breast cancer has the highest incidence rate and causes the most fatalities among all female cancers worldwide. Triple-negative breast cancer (TNBC) is known for its strong invasiveness and higher rates of recurrence. In this research, we aimed to identify MIR4435-2HG as a promising long non-coding RNA (lncRNA) biomarker and therapeutic target for TNBC. Methods: Utilizing clinicopathological information and transcriptome data from The Cancer Genome Atlas (TCGA) database, we assessed the clinical relevance of MIR4435-2HG in breast cancer through univariate and multivariate COX regression, receiver operating characteristic (ROC) analysis, as well as Kaplan-Meier survival analysis. To investigate the biological role of MIR4435-2HG in TNBC, we conducted gene set enrichment analysis (GSEA), as well as Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Additionally, we constructed and validated a nomogram to predict disease-free survival (DFS). Both the R package "pRRophetic" and the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm were employed to forecast the sensitivity to different therapeutics between the high- and low-MIR4435-2HG groups. We employed single-cell RNA sequencing analysis and tumor microenvironment infiltration analysis to investigate the potential involvement of MIR4435-2HG in the TNBC tumor microenvironment. Cellular biological behaviors were assessed utilizing CCK-8, transwell assays, and wound-healing assays. Furthermore, we performed RNA-seq, qRT-PCR, and western blotting analyses to elucidate and confirm the specific mechanisms underlying the role of MIR4435-2HG in TNBC. Results: In our study, we have identified MIR4435-2HG as a significant diagnostic and prognostic factor for TNBC. We observed that MIR4435-2HG is widely expressed and might have a significant impact on the reshaping of the TNBC tumor microenvironment. Patients with TNBC in the high-MIR4435-2HG group may show reduced sensitivity to cisplatin, doxorubicin, and gemcitabine and have an increased propensity for immune escape. Knockdown of MIR4435-2HG inhibits cancer-associated fibroblasts (CAFs) activation. Notably, MIR4435-2HG predominantly enhances the migratory and invasive capabilities of TNBC cells through the epithelial-mesenchymal transition (EMT) process. Mechanistically, we validated that MIR4435-2HG activates the JNK/c-Jun and p38 non-classical MAPK signaling pathway in TNBC cells. Conclusions: Our findings highlight the significant potential of MIR4435-2HG as a highly promising biomarker for TNBC. Targeting MIR4435-2HG could represent an appealing therapeutic approach for TNBC.

CircEGFR Reduces the Sensitivity of Pirarubicin and Regulates the Malignant Progression of Triple-Negative Breast Cancer Via the Mir-1299/Egfr Axis

CircZCCHC2 Decreases Pirarubicin Sensitivity and Promotes Triple-Negative Breast Cancer Development Via the Mir-1200/Tpr Axis

CircRNA hsa_circ_0006220 acts as a tumor suppressor gene by regulating miR-197-5p/CDH19 in triple-negative breast cancer

The Circular RNA circFGFR4 Facilitates Resistance to Anti-PD-1 of Triple-Negative Breast Cancer by Targeting the miR-185-5p/CXCR4 Axis

Circular RNA Circ_0008934 Promotes Hepatocellular Carcinoma Growth and Metastasis Through Modulating Mir-1305/Tmtc3 Axis.

Novel exosomal circEGFR facilitates triple negative breast cancer autophagy via promoting TFEB nuclear trafficking and modulating miR-224-5p/ATG13/ULK1 feedback loop

Circrad18 Sponges Mir-208A/3164 to Promote Triple-Negative Breast Cancer Progression Through Regulating IGF1 and FGF2 Expression.

CircPLK1 Sponges Mir-296-5p to Facilitate Triple-Negative Breast Cancer Progression.

Circ_0001777 Affects Triple-negative Breast Cancer Progression Through the miR-95-3p/AKAP12 Axis

Circular RNA Circ-Erbb2 Elevates the Warburg Effect and Facilitates Triple-Negative Breast Cancer Growth by the MicroRNA 136-5P/pyruvate Dehydrogenase Kinase 4 Axis.

Hsa_circ_0000199 Facilitates Chemo-Tolerance of Triple-Negative Breast Cancer by Interfering with Mir-206/613-led PI3K/Akt/mTOR Signaling.

Circrnf10 Regulates Tumorigenic Properties and Natural Killer Cell-Mediated Cytotoxicity Against Breast Cancer Through the Mir-934/Pten/pi3k-akt Axis.

Circepsti1 As a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression

Circfbxw7 Inhibits Malignant Progression by Sponging Mir-197-3p and Encoding a 185-Aa Protein in Triple-Negative Breast Cancer

CircEIF3H-IGF2BP2-HuR Scaffold Complex Promotes TNBC Progression Via Stabilizing HSPD1/RBM8A/G3BP1 Mrna.

circCDYL Acts as a Tumor Suppressor in Triple Negative Breast Cancer by Sponging miR-190a-3p and Upregulating TP53INP1

RETRACTED ARTICLE: the Circrna Circagfg1 Acts As a Sponge of Mir-195-5p to Promote Triple-Negative Breast Cancer Progression Through Regulating CCNE1 Expression

Circgfra1 and GFRA1 Act As Cernas in Triple Negative Breast Cancer by Regulating Mir-34A.

MIR4435-2HG: A novel biomarker for triple-negative breast cancer diagnosis and prognosis, activating cancer-associated fibroblasts and driving tumor invasion through EMT associated with JNK/c-Jun and p38 MAPK signaling pathway activation

EIF4A3-mediated circPRKCI expression promotes triple-negative breast cancer progression by regulating WBP2 and PI3K/AKT signaling pathway

Triple-negative Breast Cancer: Identification of circRNAs With Efficacy in Preclinical In Vivo Models